- Home
- PBYI
as 12-17-2024 4:00pm EST
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 153.2M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 416.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.47 | EPS Growth: | 492.79 |
| 52 Week Low/High: | $2.23 - $7.73 | Next Earning Date: | 11-07-2024 |
| Revenue: | $243,569,000 | Revenue Growth: | 6.30% |
| Revenue Growth (this year): | -3.07% | Revenue Growth (next year): | -7.16% |
Latest Puma Biotechnology Inc News
PBYI Breaking Stock News: Dive into PBYI Ticker-Specific Updates for Smart Investing
Business Wire
14 days ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zacks
20 days ago
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Simply Wall St.
22 days ago
Discovering Promising US Penny Stocks In November 2024
Zacks
a month ago
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
Clinical Trials Arena
a month ago
Puma commences Phase II trial of alisertib for breast cancer treatment
MT Newswires
a month ago
Puma Biotechnology Launches Mid-Stage Trial of Alisertib to Treat Breast Cancer
Business Wire
a month ago
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Simply Wall St.
a month ago
We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative
Compare PBYI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PBYI Puma Biotechnology Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.